LKG student Fatima Tauhida killed by reckless school van

Udupi, Apr 20: Patients from outside the district visiting Udupi for emergency treatment should be in possession of a certificate, issued by the district health officer or taluk health officer, that they do not have any symptoms of Covid-19.

The decision was taken during an expert committee meeting chaired by Udupi Deputy Commissioner Jagadeesha on Sunday.

The Deputy Commissioner said he will send a letter to all Deputy Commissioners in this regard. The patients from other districts will be treated in various hospitals in Udupi, only in case of emergency.

Udupi, June 21: A graduation student, who had attempted suicide two weeks ago under depression following the postponement of examinations due to covid-19, breathed his last at a private hospital yesterday. 

The deceased has been identified as Shakuntala, a final year degree student of First Grade College, Muniyal. She was a resident of Mathibettu near Vagranga in Hebri taluk. 

According to sources, she had studied hard to clear the examinations. The postponement of examinations led her to depression.  

She consumed poison at her house on June 8. She was immediately rushed to Manipal hospital where she breathed her last on June 20. A case has been registered in Hebri Police Station. 

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.